Indication intelligence, analysis and sector perception

RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting

April 10, 2023 4:40pm

The cell and gene therapy sector fluctuates in revenues, collaboration, regulatory submissions and expenses, but the changes may alarm investors who prefer to see expectation and consensus stability and share pricing growth.

Stock pricing rises or falls before and after an earnings announcement, depending on whether the earnings meet or fall short of expectations.

To date … 31 of 35 (adding BLUE, BCLI, ADVM OTCQB: BSTG)

Sage Therapeutics (SAGE) a Q4/22 net loss of -$147.1 M (FY22 -$532.8 M), or -$2.47 (FY22 -$8.98) per share, cash position $1.3 B and runway until 2025.

Ultragenyx Pharmaceuticals (RARE) a Q4/22 net loss of -$151.8 M (FY22 -$707.4 M), or -$2.16 (FY22 -$10.12) per share, cash position $896.7 M and runway until 2025.

CRISPR Therapeutics (CRSP) a Q4/22 net loss of -$110.6 M (FY22 -$650.2 M), or a Q4 -$1.41 (FY22 -$8.36) per share, cash position $1,868.4 M and runway until 2025.

Editas Medicine (EDIT) a Q4/22 net loss of -$60.7 M (FY22 -$220.M) or a Q4 -$0.88 (FY22 -$3.21) per share, cash position of $437.4M and a runway until 2025

Sangamo Therapeutics (SGMO) a Q4/22 net loss of -$52 M (FY22 -$192.3 M) or a Q4 -$0.32 (FY22 -$1.25) per share, cash position of $307.5 M <-$90.6 M ATM usage> with a runway until 2024

Alnylam Pharmaceuticals (ALNY) a Q4 net loss of -$207.4 M (FY22 - $1.31 B) or a Q4 -$1.68 (FY22 -$9.30) per share, cash position of $2.19 B with a runway until 2027.

Vericel (VCEL) a Q4/22 net income of +5.9 M (FY22 -$16.7M) or a Q4 +$0.12 (FY22 -$0.35) per share, cash position of $140 M and a runway until 2026

Intellia Therapeutics (NTLA) a Q4/22 net loss of -$113.4 M (FY22 -$474.1 M) or a Q4 -$1.40 (FY22 -$6.16) per share, cash position of $1.3 B <$337.9 M ATM usage> and a runway until 2027

uniQure NV (QURE) a Q4/22 net loss of Not Available (FY22 -$126.8M) or a Q4 -$0.15 (FY22 -$2.71) per share, cash position of $392.8 M and a runway until 2025 <eligible for $100M and +$75 M for product sale before 7/2/23>

Beam Therapeutics (BEAM) a Q4/22 net loss of -$38.3 M (FY22 -$289.1M) or a Q4 -$0.54 (FY22 -$1.43) per share, cash position of $1.1 B and a runway until 2025

Mesoblast (MESO) a Q4/22 net loss of Not Available (FY22 -$24.5M) or a Q4 Not Available (FY22 -$3.32) per share, cash position of $67.7 M <ATM usage of $30 M> and a runway until mid-2025

Chinook Therapeutics (KDNY) a Q4/22 net loss of -$62.6 M (FY22 -$187.9 M) or a Q4 -$0.90 (FY22 -$2.92) per share, cash position of $385.3 M and a runway until 2025

Regenxbio (RGNX) a Q4/22 net loss of -$59.9 M (FY22 -$282.8 M), a Q4 -$0.58 (FY22 -$6.87) per share, cash position $565.2 M and runway until 2025

Fate Therapeutics (FATE) a Q4/22 net loss of -$54.9 M (FY22 -$294 M), a Q4 -$1.38 (FY22 -$2.91) per share, cash position $441.2 M and runway until 2025 <a $38.5 m receivable 12/31/22>

MiMedx (MDXG) a Q4/22 net loss of -$41.5 M (FY22 -$30.19 M), a Q4 -$0.02 (FY22 -$0.33) per share, cash position $66 M and runway until 2025

Precigen (PGEN) a Q4 net loss of -$22.2 M (FY22 -$79.8 m) or -$0.11 (FY22 -$0.40) per share, cash position of $99.7 M <$73 M offering 1/23> and a runway of 2025

Voyager Therapeutics (VYGR) a Q4/22 net loss of -$23.6 M (FY22 -$46.4 M), or -$0.61 (FY22 -$1.21) per share, cash position $118.8 M and runway until 2025.

Cellectis SA (CLLS) a Q4/22 net loss of -$28.5 M (FY22 -$114 M), -$0.59 (FY22 -$2.33) per share, cash position $95 M and runway until 2025

Prime Medicine (PRME) a Q4/22 net loss of -$39.3 M (FY22 -$121.8 M), -$0.56 (FY22 -$4.19) per share, cash position $293.9 M and runway until 2025

Caribou Biosciences (CRBU) a Q4/22 net loss of -$27 M (FY22 -$99.4 M), -$0.44 (FY22 -$1.64) per share, cash position $317 M and runway until 2025

Homology Medicine (FIXX) a Q4/22 net loss of -$34.3 M (FY22 -$5 M), -$0.60 (FY22 -$1.73) per share, cash position $175 M and runway until Q4/24

Agenus (AGEN) a Q4/22 net loss of -$74.1 M (FY22 -$230.5 M), -$0.24 (FY22 -$0.78) per share, cash position $193 M and runway until 2025

AxoGen (AXGN) a Q4/22 adjusted net loss of -$1.08 M (FY22 -$12.6 M), -$0.13 (FY22 -$0.30) per share, cash position $55 M and runway until 2025

Verastem Oncology (VSTM) a Q4/22 net loss of -$16.8 M (FY22 -$73.8 M), -$0.08 (FY22 -$0.38) per share, cash position $87.9 M <ATM draw down -$15 M and raised $117.9 M in convert notes) and runway until 2025

Compass Therapeutics (CMPX) a Q4/22 net loss of -$11.5 M (FY22 -$29.2 M), or -$0.10 (FY22 -$0.37) per share, cash position $186.6 M and runway until 2025.

BioLife Solutions (BLFS) an unaudited Q4/22 net loss of -$49.2 M (FY22 -$139.8 M), -$1.15 (FY22 -$3.29) per share, cash position $64.1 M and runway until 2025

Avrobio (AVRO) a Q4/22 net loss of -$25 M (FY22 -$105.29 M), -$0.57 (FY22 -$2.42) per share, cash position $9.6 and runway until Q4/23

Solid Biosciences (SLDB) a Q4/22 net loss of -$15.2 M (FY22 -$86 M), -$N/A (FY22 -$10.10) per share, cash position $213.7 M and runway until 2025

bluebird bio (BLUE) a Q4/22 net loss of -$32.2 M (FY22 -$266.6 M), -$0.38 (FY22 -$3.39) per share, cash position $227 M +$131 M for PRV sale (1/23) and runway until Q4/2024

Brainstorm Cell Therapeutics (BCLI) a FY22 -$24.3 M, or -$0.66 per share, cash position $3 M and runway until Q2/2023

Adverum Biotechnologies (ADVM) a Q4/22 net loss of -$32.7 M (FY22 -$154.4 M), -$0.33 (FY22 -$1.56) per share, cash position $185.6 M and runway until 2025

Biostage (OTCQB: BSTG) a FY/22 net loss of -$6.073 M or -$0.54 per share, cash position $1.21 M and runway until Q2/2023

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.